Strategy is Cheap. Execution drives Medical Device earnings from 2/2/26 - 2/7/26

The third wave of earnings (Boston Scientific, GE HealthCare, Siemens Healthineers, STERIS) just confirmed a hard truth for 2026: The market cares less about your 5 year plan in this ever shifting economic, political climate. Focus on execution to drive results and stock price.

We are seeing a clear divide open up between the "Operators" and the "Generalists." The Operators are winning by ruthlessly prioritizing their portfolios and pricing. The Generalists are being left behind.

MedTech Performance Map: Q4 2025 Reporting Cycle

This list will continue to grow. Come back in the coming weeks for an update.

2026 Q4 Earnings Summary for Medical Device Execs.2.9.26.pdf

Download PDF • 188KB

Here are the three execution lessons from this week’s earnings that you need to take back to your team.

1. Portfolio Pruning: Addition by Subtraction

The "conglomerate safety net" is gone. Last week, Conmed took a hit to exit Gastroenterology. This week, the giants followed suit.

• The Move: Siemens Healthineers and GE HealthCare are actively de-consolidating or spinning off "drag" assets (like Diagnostics) to protect their high-growth imaging cores.

• The Lesson: Growth at the expense of focus is no longer rewarded. If a business unit is diluting your focus or your margins, the most strategic move is to cut it.

2. The "All-In" Bet

Boston Scientific isn't hedging. They identified Pulsed Field Ablation (PFA) as the future of cardiac care, and they went all in.

• The Result: Double-digit organic growth that is outpacing the market.

• The Lesson: You can't win everywhere. Pick your "PFA"—the one technology or segment where you must win—and resource it until you dominate. Everything else is secondary.

3. Pricing Discipline as a Skill

STERIS proved that tariffs don't have to kill your quarter.

• The Execution: They didn't just "absorb" the cost; they successfully passed it through to customers while shifting their mix toward higher-margin service contracts.

• The Lesson: Pricing power isn't luck; it's a discipline. If you aren't training your sales force to defend price now, you are already too late for the 2026 tariff cycle.

The Executive Gut Check The focus on execution is helping these companies win. How are you helping to drive focus in your company?

If you can’t answer that question in one sentence, you (and your 2026 guidance) may be at risk.